Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis.
Antimicrob Agents Chemother
; 44(3): 619-21, 2000 Mar.
Article
en En
| MEDLINE
| ID: mdl-10681328
The efficacy of FK463, a novel water-soluble lipopeptide, was evaluated in mouse models of pulmonary aspergillosis and was compared with that of amphotericin B (AMPH-B). In the pulmonary aspergillosis models induced by intranasal inoculation, FK463 exhibited good efficacy, with 50% effective doses in the range of 0. 26 to 0.51 mg/kg of body weight; these values were comparable to those of AMPH-B. In an Aspergillus target organ assay with immunosuppressed mice, under conditions of constant plasma levels of FK463, using a subcutaneously implanted osmotic pressure pump, a significant reduction in viable fungal cells was observed at plasma FK463 levels of 0.55 to 0.80 microgram/ml or higher. We conclude that FK463 is highly effective in the treatment of pulmonary aspergillosis in this animal model. These results indicate that FK463 may be a potent parenterally administered antifungal agent for pulmonary aspergillosis.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Péptidos Cíclicos
/
Aspergilosis
/
Aspergillus fumigatus
/
Lipoproteínas
/
Enfermedades Pulmonares Fúngicas
/
Antifúngicos
Límite:
Animals
Idioma:
En
Revista:
Antimicrob Agents Chemother
Año:
2000
Tipo del documento:
Article
País de afiliación:
Japón
Pais de publicación:
Estados Unidos